Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis

Abstract Background Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still debated. We conducted a meta-analysis to eval...

Full description

Bibliographic Details
Main Authors: Francesca De Felice, Ilaria Benevento, Anna Lisa Magnante, Daniela Musio, Nadia Bulzonetti, Rossella Caiazzo, Vincenzo Tombolini
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Cancer
Subjects:
Locally advanced rectal cancer
Oxaliplatin
Fluoruracil
Neoadjuvant treatment
Chemoradiotherapy
Survival
Online Access:http://link.springer.com/article/10.1186/s12885-017-3323-4

Internet

http://link.springer.com/article/10.1186/s12885-017-3323-4

Similar Items